R20. Development of sustained release gastroretentive floating tablets using HME coupled 3D printing: A QbD approach

Nagireddy Dumpa  
*University of Mississippi*, nagireddy.dumpa@gmail.com

Arun Butreddy  
*University of Mississippi*

Suresh Bandari  
*University of Mississippi*

Michael A. Repka  
*University of Mississippi*

Follow this and additional works at: [https://egrove.olemiss.edu/pharm_annual_posters](https://egrove.olemiss.edu/pharm_annual_posters)

**Recommended Citation**
[https://egrove.olemiss.edu/pharm_annual_posters/20](https://egrove.olemiss.edu/pharm_annual_posters/20)
Development of sustained release gastroretentive floating tablets using HME coupled 3D printing: A QbD approach

Nagi Reddy Dumpa1, Arun Butreddy2, Suresh Bandari3, Michael A. Repka1,2
1Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi
2Pi Center for Pharmaceutical Technology, The University of Mississippi, University, MS-38677, USA
Email: ndumpa@go.olemiss.edu

PURPOSE
The main objective of this study was to develop sustained release gastroretentive floating tablets using fused filament fabrication (FFF) 3D printing and evaluate the effect of formulation and process variables on in vitro drug release characteristics using Quality by Design (QbD) approach.

METHODS
Hot Melt Extrusion: Hydroxypropyl methylcellulose (HPMC E5), ethyl cellulose (EC-N14), and acetaminophen (APAP) (model drug) were blended using maxblend™ (globepharma, new brunswick, NJ, USA) at 25 rpm for 15 minutes. A 11mm twin screw extruder (thermo fisher scientific, waltham, MA, USA) was used to extrude cylindrical filaments with a 1.75mm diameter to be used as feedstock material for 3D printing.

3D Printing: The tablets were designed as hollow cylindrical objects (d=12.4mm, h=5mm) to decrease density and float in gastric medium, using tinkercad™ free online software (autodesk, CA, USA). Combining both these digital files and previously extruded filaments, the gastroretentive floating tablets were prepared using a FFF based 3D printer (prusa i3 3D desktop printer, prusa research, prague, czech republic). The formulation variables (% drug load, EC concentration) and process variables (shell thickness) were chosen as independent variables and % drug release at 2h, 6h and 10h were chosen as dependent variables (Table 1, 2 & 3). A response surface method with three-factor, three-level box-behnken design was applied for the optimization of sustained release floating tablets.

Characterization: Thermal stability of polymers in the study was assessed using thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). Mechanical properties of the extruded filaments were determined using a texture analyzer (TA-XT2i analyzer, texture technologies, MA, USA). (Figure 1). The printed tablets were evaluated for in vitro drug release and floating ability in 0.1N HCl dissolution media. (Figure 2).

The coefficients of % APAP are positive implying that drug dissolution increases with increase in API load. Whereas the coefficients of both shell thickness and % EC are negative indicating drug dissolution decreases with increase in shell thickness or % EC.

% EC had greatest effect on drug release profiles whereas shell thickness had the least effect.

Both % APAP and % EC significantly influenced the drug release at 2h, 6h and 10h (p<0.05), where as shell thickness had significant effect at only 2h and 6h and lost effect at 10 h (p=0.0036) (Table 4.)

No interaction is seen between all three factors (p>0.05), but at 10h, when shell thickness lost effect, there is an interaction between drug load and % EC (p=0.0053) (Table 4.).

APAP, is freely water-soluble drug, so as the % APAP increased in formulation, the drug release increased.

EC is a hydrophobic and water insoluble polymer, so as % EC is increased, drug release decreased

Shell has separate fill pattern and denser structure compared to core of tablet. So higher shell thickness successfully prevents the entry of dissolution media for longer time and resulted in reduced drug release.

CONCLUSIONS
✓ Filaments suitable for FFF 3D printing were successfully fabricated using different ratios HPMC, EC and APAP.
✓ All the three independent factors studied had significant effect on drug release profiles.
✓ QbD was applied to assess the effect of formulation and process parameters on in vitro drug release characteristics.
✓ Sustained release gastroretentive floating tablets were prepared with HME coupled 3D printing.
✓ All the printed tablets exhibited good floating behavior throughout the dissolution studies.
✓ FFF 3D printing coupled with QbD is a novel viable tool for fabricating customized dosage forms for personalized pharmacotherapy.

ACKNOWLEDGEMENTS
Authors acknowledge Pi Center for Pharmaceutical Technology.

This project was also partially supported by Grant Number P30GM122733-01A1, funded by the National Institute of General Medical Sciences (NIGMS) a component of the National Institutes of Health (NIH) as one of its Centers of Biomedical Research Excellence (COBRE).